Sunesis Pharmaceuticals (SNSS) Earning Somewhat Favorable Media Coverage, Report Shows

News articles about Sunesis Pharmaceuticals (NASDAQ:SNSS) have been trending somewhat positive on Thursday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sunesis Pharmaceuticals earned a news impact score of 0.14 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 47.0694587803928 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Several research firms have weighed in on SNSS. Cantor Fitzgerald reiterated a “hold” rating and set a $4.00 price target on shares of Sunesis Pharmaceuticals in a research note on Thursday, March 8th. ValuEngine downgraded Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Zacks Investment Research downgraded Sunesis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, February 15th. Finally, Cowen reiterated a “hold” rating on shares of Sunesis Pharmaceuticals in a research note on Tuesday, May 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $4.12.

Get Sunesis Pharmaceuticals alerts:

Sunesis Pharmaceuticals traded up $0.05, hitting $2.51, during trading hours on Thursday, Marketbeat Ratings reports. 202 shares of the stock traded hands, compared to its average volume of 79,787. The company has a market cap of $95.55 million, a PE ratio of -1.73 and a beta of 1.79. Sunesis Pharmaceuticals has a 1 year low of $1.82 and a 1 year high of $7.69.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.06. The firm had revenue of $0.24 million for the quarter. analysts expect that Sunesis Pharmaceuticals will post -0.97 EPS for the current fiscal year.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.